Baricitinib plus remdesivir shows promise in hospitalized patients

Dec 14, 2020 - 03:18 PM
FDA product update

Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published Friday in the New England Journal of Medicine.

The therapy appeared to benefit patients requiring high-flow oxygen or non-invasive ventilation most, reducing their median time to recovery from 18 days to 10 days, researchers said.

The clinical trial is the second in the National Institutes of Health Adaptive COVID-19 Treatment Trial, a study to evaluate therapeutics for people hospitalized with COVID-19. 

The Food and Drug Administration last month authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

Related News Articles

Headline
Study finds driving with COVID-19 raises crash risk by 25%
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
Senate Finance Committee advances RFK Jr. nomination for HHS secretary
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
CDC: Flu activity remains high, COVID-19 increasing while RSV peaks 
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
OSHA ends efforts to establish COVID-19 safety standard 
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
Certain PREP Act liability protections for COVID-19 countermeasures extended through 2029 
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
View the AHA's latest United Against the Flu toolkit celebrating fall
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…